Search Results - "Aznar, María Angela"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Downregulation of FOXP1 is required during germinal center B-cell function by Sagardoy, Ainara, Martinez-Ferrandis, Jose I., Roa, Sergio, Bunting, Karen L., Aznar, María Angela, Elemento, Olivier, Shaknovich, Rita, Fontán, Lorena, Fresquet, Vicente, Perez-Roger, Ignacio, Robles, Eloy F., De Smedt, Linde, Sagaert, Xavier, Melnick, Ari, Martinez-Climent, Jose A.

    Published in Blood (23-05-2013)
    “…B-cell maturation and germinal center (GC) formation are dependent on the interplay between BCL6 and other transcriptional regulators. FOXP1 is a transcription…”
    Get full text
    Journal Article
  2. 2

    For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity by Marquez-Rodas, Ivan, Aznar, María Angela, Calles, Antonio, Melero, Ignacio

    Published in Clinical cancer research (15-02-2019)
    “…Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic…”
    Get full text
    Journal Article
  3. 3

    Edelfosine Lipid Nanoparticles Overcome Multidrug Resistance in K‑562 Leukemia Cells by a Caspase-Independent Mechanism by Aznar, María Ángela, Lasa-Saracíbar, Beatriz, Blanco-Prieto, Maria J

    Published in Molecular pharmaceutics (04-08-2014)
    “…The antitumor ether lipid edelfosine is the prototype of a novel generation of promising anticancer drugs that has been shown to be an effective antitumor…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Efficacy of edelfosine lipid nanoparticles in breast cancer cells by Aznar, María Ángela, Lasa-Saracíbar, Beatriz, Estella-Hermoso de Mendoza, Ander, Blanco-Prieto, María José

    Published in International journal of pharmaceutics (01-10-2013)
    “…Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units. It represents the leading cause of cancer…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Lipid nanoparticles protect from edelfosine toxicity in vivo by Lasa-Saracíbar, Beatriz, Aznar, María Ángela, Lana, Hugo, Aizpún, Ismael, Gil, Ana Gloria, Blanco-Prieto, Maria J.

    Published in International journal of pharmaceutics (20-10-2014)
    “…[Display omitted] Edelfosine, an alkyl-lysophospholipid antitumor drug with severe side-effects, has previously been encapsulated into lipid nanoparticles (LN)…”
    Get full text
    Journal Article
  10. 10